

References for CRNX Pitch on Sept 24, 2025 by Nicole Malofsky:

- 1) <https://www.researchandmarkets.com/report/rare-endocrine-disease-drug>
- 2) <https://crinetics.com/crinetics-announces-fda-acceptance-of-new-drug-application-for-paltusotine-for-adult-patients-with-acromegaly/>
- 3) <https://www.businessresearchinsights.com/market-reports/rare-endocrine-disease-treatment-market-111940>
- 4) <https://www.sidley.com/en/insights/newsupdates/2025/07/key-inflation-reduction-act-amendment-broadens-us-protection-for-orphan-drugs>
- 5) <https://crinetics.com/crinetics-pharmaceuticals-reports-second-quarter-2025-financial-results-and-provides-business-update/>
- 6) <https://ir.crinetics.com/news/news-details/2024/CRINETICS-LAUNCHES-ACROTRUTH-EDUCATIONAL-INITIATIVE-TO-RAISE-AWARENESS-OF-ACROMEGALY-TREATMENT-CHALLENGES-08-08-2024/default.aspx>
- 7) <https://www.sidley.com/en/insights/newsupdates/2025/07/key-inflation-reduction-act-amendment-broadens-us-protection-for-orphan-drugs>
- 8) <https://www.researchandmarkets.com/report/rare-endocrine-disease-drug>
- 9) <https://media.market.us/acromegaly-treatment-market-news-2025/>
- 10) <https://d18rn0p25nwr6d.cloudfront.net/CIK-0001658247/d6c55280-5012-48b0-a551-0a1dd08c14e6.pdf>
- 11) <https://crinetics.com/pipeline/>
- 12) https://go.bio.org/rs/490-EHZ-999/images/ClinicalDevelopmentSuccessRates2011_2020.pdf
- 13) <https://crinetics.com/crinetics-once-daily-oral-paltusotine-achieved-the-primary-and-all-secondary-endpoints-in-the-phase-3-pathfndr-2-study-in-acromegaly-patients/>
- 14) https://crinetics.com/wp-content/uploads/2024/11/Zhao-et-al-NANET-2024-NDC-Poster_final-18Nov24.pdf
- 15) <https://www.mayoclinic.org/diseases-conditions/acromegaly/diagnosis-treatment/drc-20351226>
- 16) <https://pubmed.ncbi.nlm.nih.gov/34173129/>
- 17) https://crinetics.com/wp-content/uploads/2024/03/PF2-Ph3-Investor-Deck-3-18-24_Webcast-FINAL.pdf
- 18) <https://www.sciencedirect.com/science/article/abs/pii/S1521690X24000605>
- 19) <https://crinetics.com/crinetics-once-daily-oral-paltusotine-achieved-the-primary-and-all-secondary-endpoints-in-the-phase-3-pathfndr-2-study-in-acromegaly-patients/>
- 20) <https://crinetics.com/crinetics-announces-positive-initial-findings-at-endo-2024-for-atumelnant-in-two-ongoing-open-label-studies-for-the-treatment-of-congenital-adrenal-hyperplasia-cah-and-acth-dependent-cushing/>
- 21) https://go.bio.org/rs/490-EHZ-999/images/ClinicalDevelopmentSuccessRates2011_2020.pdf
- 22) <https://ir.crinetics.com/news/news-details/2025/Crinetics-Pharmaceuticals-Reports-Second-Quarter-2025-Financial-Results-and-Provides-Business-Update/default.aspx>
- 23) <https://crinetics.com/our-company/r-scott-struthers-phd-founder-chief-executive-officer/>
- 24) <https://www.fiercebitech.com/biotech/lilly-signs-140m-upfront-partnership-radionectics-latest-radiopharma-play>
- 25) <https://ir.crinetics.com/news/news-details/2024/EY-ANNOUNCES-SCOTT-STRUTHERS-PH-D--CEO-AND-FOUNDER-OF-CRINETICS-PHARMACEUTICALS-AS-AN-ENTREPRENEUR-OF-THE-YEAR-2024-PACIFIC-SOUTHWEST-AWARD-WINNER-06-18-2024/default.aspx>
- 26) <https://www.google.com/finance/beta/quote/CRNX:NASDAQ>
- 27) <https://crinetics.com/crinetics-pharmaceuticals-reports-second-quarter-2025-financial-results-and-provides-business-update/>
- 28) <https://crinetics.com/crinetics-closes-initial-public-offering/>
- 29) <https://ir.crinetics.com/news/news-details/2025/CRINETICS-PHARMACEUTICALS-ANNOUNCES-EUROPEAN-MEDICINES-AGENCY-EMA-VALIDATION-OF-MARKETING-AUTHORIZATION->

APPLICATION-MAA-AND-ORPHAN-DRUG-DESIGNATION-ODD-FOR-PALTUSOTINE-IN-
ACROMEGALY-03-27-2025/default.aspx